Evidence map›Paper›PMID 30787926›Full record

ArticleFrontiers in immunology2019

Mutation S110L of H1N1 Influenza Virus Hemagglutinin: A Potent Determinant of Attenuation in the Mouse Model.

Amelia Nieto, Jasmina Vasilijevic, Nuno Brito Santos, Noelia Zamarreño, Pablo López, Maria Joao Amorim, Ana Falcon

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Amelia NietoNational Center for Biotechnology (CNB-CSIC), Madrid, Spain.
Jasmina VasilijevicNational Center for Biotechnology (CNB-CSIC), Madrid, Spain.
Nuno Brito SantosCell Biology of Viral Infection Lab, Instituto Gulbenkian de Ciência, Oeiras, Portugal.
Noelia ZamarreñoNational Center for Biotechnology (CNB-CSIC), Madrid, Spain.
Pablo LópezNational Center for Biotechnology (CNB-CSIC), Madrid, Spain.
Maria Joao AmorimCell Biology of Viral Infection Lab, Instituto Gulbenkian de Ciência, Oeiras, Portugal.
Ana FalconNational Center for Biotechnology (CNB-CSIC), Madrid, Spain.
Centro Nacional de Biotecnología · ESCentre for Biomedical Network Research on Rare Diseases · ESInstituto Gulbenkian de Ciência · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Characterization of a pandemic 2009 H1N1 influenza virus isolated from a fatal case patient (F-IAV), showed the presence of three different mutations; potential determinants of its high pathogenicity that were located in the polymerase subunits (PB2 A221T and PA D529N) and the hemagglutinin (HA S110L). Recombinant viruses containing individually or in combination the polymerase mutations in the backbone of A/California/04/09 (CAL) showed that PA D529N was clearly involved in the increased pathogenicity of the F-IAV virus. Here, we have evaluated the contribution of HA S110L to F-IAV pathogenicity, through introduction of this point mutation in CAL recombinant virus (HA mut). The HA S110L protein has similar pH stability, comparable mobility, and entry properties both in human and mouse cultured cells that wild type HA. The change HA S110L leads to a non-significant trend to reduce the replication capacity of influenza virus in tissue culture, and HA mut is better neutralized than CAL virus by monoclonal and polyclonal antibodies against HA from CAL strain. In addition, recombinant viruses containing HA S110L alone or in combination with polymerase mutations considerably increased the LD50 in infected mice. Characterization of the lungs of HA mut infected animals showed reduced lung damage and inflammation compared with CAL infected mice. Accordingly, lower virus replication, decreased presence in bronchioli and parenchyma and lower leukocytes and epithelial infected cells were found in the lungs of HA mut-infected animals. Our results indicate that, mutation HA S110L constitutes a determinant of attenuation and suggest that its interaction with components of the respiratory tract mucus and lectins, that play an important role on influenza virus outcome, may constitute a physical barrier impeding the infection of the target cells, thus compromising the infection outcome.

Indexed as

AnimalsCells, CulturedDisease Models, AnimalHemagglutinin Glycoproteins, Influenza VirusHumansImmunityInfluenza A Virus, H1N1 SubtypeInfluenza, HumanLungMiceMutationOrthomyxoviridae InfectionsVirulenceVirus InternalizationVirus ReplicationH1N1 virus hemagglutininHemagglutinin Glycoproteins, Influenza VirusattenuationHA S110L mutationinfluenza virusin vivo pathogenicityviral entry

Identifiers

PMID30787926
PMCPMC6372558
OpenAlexW2912906566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.